The present technology generally relates to implantable medical devices and, in particular, to intraocular shunting systems and associated methods for selectively controlling fluid flow between different portions of a patient's eye.
Glaucoma is a degenerative ocular condition involving damage to the optic nerve that can cause progressive and irreversible vision loss. Glaucoma is frequently associated with ocular hypertension, an increase in pressure within the eye resultant from an increase in production of aqueous humor (“aqueous”) within the eye and/or a decrease in the rate of outflow of aqueous from within the eye into the blood stream. Aqueous is produced in the ciliary body at the boundary of the posterior and anterior chambers of the eye. It flows into the anterior chamber and eventually into the capillary bed in the sclera of the eye. Glaucoma is typically caused by a failure in mechanisms that transport aqueous out of the eye and into the blood stream.
Many aspects of the present technology can be better understood with reference to the following drawings. The components in the drawings are not necessarily drawn to scale. Instead, emphasis is placed on illustrating clearly the principles of the present technology. Furthermore, components can be shown as transparent in certain views for clarity of illustration only and not to indicate that the component is necessarily transparent. Components may also be shown schematically.
The present technology is generally directed to adjustable shunting systems for draining fluid from a first body region to a second body region. The adjustable shunting systems include a plate assembly (e.g., a flow control plate or cartridge) for controlling the flow of fluid through the system. For example, the plate assembly can include a shape memory actuation assembly having one or more nitinol actuators for controlling the flow of fluid through the system. The plate assembly can further include a plurality of discrete sheets or layers adhered together to encase the shape memory actuation assembly. The discrete sheets or layers can form flow channels for directing fluid through the flow control plate.
The terminology used in the description presented below is intended to be interpreted in its broadest reasonable manner, even though it is being used in conjunction with a detailed description of certain specific embodiments of the present technology. Certain terms may even be emphasized below however, any terminology intended to be interpreted in any restricted manner will be overtly and specifically defined as such in this Detailed Description section. Additionally, the present technology can include other embodiments that are within the scope of the examples hut are not described in detail with respect to
Reference throw out this specification to “one embodiment” or “an embodiment” means that a particular feature, structure, or characteristic described in connection with the embodiment is included in at least one embodiment of the present technology. Thus, the appearances of the phrases “in one embodiment” or “in an embodiment” in various places throughout this specification are not necessarily all referring to the same embodiment. Furthermore, the particular features or characteristics may be combined in any suitable manner in one or more embodiments.
As used herein, the use of relative terminology, such as “about”, “approximately”, “substantially” and the like refer to the stated value plus or minus ten percent. For example, the use of the term “about 100” refers to a range of from 90 to 110, inclusive. In instances in which the context requires otherwise and/or relative terminology is used in reference to something that does not include a numerical value, the terms are given their ordinary meaning to one skilled in the art. Reference throughout this specification to the term “resistance” refers to fluid resistance unless the context clearly dictates otherwise. The terms “drainage rate” and “flow” are used interchangeably to describe the movement of fluid through a structure.
Although certain embodiments herein are described in terms of shunting fluid from an anterior chamber of an eye, one of skill in the art will appreciate that the present technology can be readily adapted to shunt fluid from and/or between other portions of the eye, or, more generally, from and/or between a first body region and a second body region. Moreover, while the certain embodiments herein are described in the context of glaucoma treatment, any of the embodiments herein, including those referred to as “glaucoma shunts” or “glaucoma devices” may nevertheless be used and/or modified to treat other diseases or conditions, including other diseases or conditions of the eye or other body regions. For example, the systems described herein can be used to treat diseases characterized by increased pressure and/or fluid build-up, including but not limited to heart failure (e.g., heart failure with preserved ejection fraction, heart failure with reduced ejection fraction, etc.), pulmonary failure, renal failure, hydrocephalus, and the like. Moreover, while generally described in terms of shunting aqueous, the systems described herein may be applied equally to shunting other fluid, such as blood or cerebrospinal fluid, between the first body region and the second body region.
The system 100 includes a generally elongated housing 102 and a plate assembly 120. The elongated housing 102 (which can also be referred to as a casing, membrane, shunting element, or the like) extends between a first end portion 102a and a second end portion 102b. The elongated housing 102 includes a window or other opening 109 providing access to a chamber 108, which, as described in greater detail below, is configured to receive and house the plate assembly 120. The elongated housing 102 further includes a manifold or fluid collection area 111, and one or inure main fluid conduits 110 fluidly coupling the manifold 111 to one or more fluid outlets 106 positioned proximate the second end portion 102b. In some embodiments, the elongated housing 102 is composed of a slightly elastic or flexible biocompatible material (e.g., silicone, etc.). In some embodiments, the elongated housing can have one or more ridges 113 to prevent the main fluid conduit(s) 110 from collapsing. The elongated housing 102 can also have one or more wings or appendages 112 having holes (e.g., suture holes) for securing the elongated housing 102 in a desired position.
The plate assembly 120 (which can also be referred to as a flow control plate, a flow control cartridge, a plate structure, or the like) is positioned within the chamber 108 and is configured to control the flow of fluid through the system 100. For example, the plate assembly 120 includes one or more fluid inlets 104 (e.g., a first fluid inlet 104a, a second fluid inlet 104b, and a third inlet 104c) that permit fluid to enter the plate assembly 120 (and thus the elongated housing 102) from an environment external to the system 100. In some embodiments, the upper surface of the plate assembly 120 forms a substantial fluid seal with the elongated housing 102 such that the only way for fluid to enter the system 100 is through the fluid inlets 104.
The plate assembly 120 is configured to selectively control the flow of fluid entering the system 100. For example, the plate assembly 120 includes a first actuator 122a configured to control the flow of fluid through the first fluid inlet 104a, a second actuator 122b configured to control the flow of fluid through the second fluid inlet 104b, and a third actuator 122c configured to control the flow of fluid through the third fluid inlet 104c. In particular, the first actuator 122a can include a first projection or gating element 124a configured to moveably interface with the first, fluid inlet, 104a, e.g., to move between a first open position in which the first gating element 124a does not substantially prevent fluid from flowing through the first fluid inlet 104a and a second closed position in which the first gating element 124a substantially prevents fluid from flowing through the first fluid inlet 104a. The second actuator 122b can include a second gating element 124b and the third actuator 122c can include a third gating element 124c that operate in a similar manner as the first gating element 124a (e.g., moveable between open and closed positions relative to the second fluid inlet 104b and the third fluid inlet 104c).
The first actuator 122a can further include a first actuation element 126a1 and a second actuation element 126a2 that drive movement of the first gating element 124a between the open position and the closed position. The first actuation element 126a1 and the second actuation element 126a2 can be composed at least partially of a shape memory material or alloy (e.g., nitinol). Accordingly, the first actuation element 126a1 and the second actuation element 126a2 can be transitionable at least between a first material phase or state (e.g., a martensitic state, a R-phase, a composite state between martensitic and R-phase, etc.) and a second material phase or state (e.g., an austenitic state, an R-phase state, a composite state between austenitic and R-phase, etc.). In the first material state, the first actuation element 126a1 and the second actuation element 126a2 may have reduced (e.g., relatively less stiff) mechanical properties that cause the actuation elements to be more easily deformable (e.g., compressible, expandable, etc.) relative to when the actuation elements are in the first material state. In the second material state, the first actuation element 126a1 and the second actuation element 126a2 may have increased (e.g., relatively more stiff) mechanical properties relative to the first material state, causing an increased preference toward a specific preferred geometry (e.g., original geometry, manufactured or fabricated geometry, heat set geometry, etc.). The first actuation element 126a1 and the second actuation element 126a2 can be selectively and independently transitioned between the first material gate and the second material gate by applying energy (e.g., laser energy, heat, electrical energy, etc.) to the first actuation element 126a1 or the second actuation element 126a2 to heat it above a transition temperature.
The first actuation element 126a1 and the second actuation element 126a2 generally act in opposition. For example, the first actuation element 126a1 can be actuated to move the first gating element 124a toward the closed position, and the second actuation element 126a2 can be actuated to move the first gating element 124a toward the open position. Additionally, the first actuation element 126a1 and the second actuation element 126a2 are coupled such that as one moves toward its preferred geometry upon material phase transition, the other is deformed relative to its preferred geometry. This enables the actuation elements to be repeatedly actuated and the first gating element 124a to be repeatedly cycled between the open position and the closed position. The second actuator 122b and the third actuator 122c can also each include a pair of opposing shape-memory actuators and operate in the same or similar fashion as the first actuator 122a. Additional details regarding the operation of shape memory actuators, as well as adjustable glaucoma shunts, are described in U.S. Patent App. Publication Nos. 2020/0229982 and 2021/0251806, and International Patent Application Nos. PCT/US2020/055144 and PCT/US2020/055141, the disclosures of which are incorporated by reference herein in their entireties and for all purposes. Additional details of the plate assembly 120 are described with respect to
In operation, the system 100 can be used to drain aqueous from the anterior chamber of the eye to treat glaucoma. Accordingly, when the system 100 is implanted in an eye to treat glaucoma, the first end portion 102a of the elongated housing 102 can be positioned within an anterior chamber of the patient's eye such that the fluid inlets 104 are in fluid communication with the anterior chamber, and the second end portion 102b can be positioned in a target outflow location, such as a subconjunctival bleb space, such that the fluid outlets 106 are in fluid communication with the target outflow location. As described in greater detail below, aqueous can flow into the elongated housing via the fluid inlets 104, through the plate assembly 120, into the main fluid conduit 110, and exit via the fluid outlets 106.
As described in more detail below, the relative level of therapy provided by each fluid inlet 104 can be different so that a user may selectively control the flow through the system 100 by selectively interfering with or permitting flow through individual fluid inlets 104. For example, under a given pressure, when flow primarily occurs through the first fluid inlet 104a, the system 100 can provide a first drainage rate, when flow primarily occurs through the second fluid inlet 104b, the system 100 can provide a second drainage rate greater than the first drainage rate, and when flow primarily occurs through the third fluid inlet 104c, the system 100 can provide third drainage rate greater than the first drainage rate. The foregoing difference in drainage rates can be achieved by varying the fluid resistance of channels (e.g., channels 254a-c, shown in
Although described as having three inlets 104 and three actuators 122, the plate assembly 120 can have more or fewer inlets 104 and actuators 122. For example, the plate assembly 120 can have one, two, four, five, six, or M ore inlets 104 and actuators 122,
The sheets 230-260 are configured to stack atop, adhere to, or be adhered to one another, e.g., to form a cartridge. In particular, an upper surface of the second sheet 240 is configured to engage and adhere to a lower surface of the third sheet 250, an upper surface of the third sheet 250 is configured to engage and adhere to a lower surface of the fourth sheet 260, and an upper surface of the fourth sheet 260 is configured to engage and adhere to a lower surface of the first sheet 230. When the sheets 230-260 are stacked atop and adhered to one another, the boundaries between adjacent sheets of the sheets 230-260 are or can be fluidically sealed to prevent fluid from leaking into or out of the plate assembly. The sheets 230-260 can be adhered through any suitable technique, including gluing, welding, soldering, bonding, or the like. In some embodiments, the sheets 230-260 are self-bonding and automatically adhere to one another if placed un der certain conditions (e.g. in a vacuum). In some embodiments, rather than adhering the sheets 230-260 to one another, the sheets 230-260 are placed within a case or other membrane that holds the sheets 230-260 in the desired orientation. In such embodiments, the gaps between adjacent sheets can be partially or fully sealed using a sealant to prevent unwanted fluid leakage between adjacent sheets.
The sheets 230-260 encompass the actuation assembly 221. For example, the fourth sheet 260 defines an outer frame with an empty interior 262 that is sized and shaped to receive the actuation assembly 221. Accordingly, when the sheets 230-260 are stacked atop and adhered to one another, the actuation assembly 221 sits within the empty interior 262 of the fourth sheet 260 (e.g., the fourth sheet 260 at least partially encircles a lateral boundary of the actuation assembly 221) and between the third sheet 250 and the first sheet 230. One or more of the sheets 230-260 can be composed of a transparent material. That way, light (e.g. laser) energy can be applied to actuate (e.g., heat) the actuators 122 even when the actuation assembly 221 is fully enclosed within the sheets 230-260. For example, in some embodiments, the first sheet 230 is composed of quartz (e.g., silicon dioxide), glass, alumina (sapphire) metals (e.g., Si, Pt, Au, etc.), plastic, and/or other suitable material, and a user directs laser energy through the first sheet 230 to one or more actuators 122. In some embodiments, all of the sheets 230-260 are composed of the same material (e.g., glass). In some embodiments, the material is substantially rigid. In some embodiments, the first sheet 230 may not be fully transparent, but instead may include one or more transparent windows aligned with the actuators 122.
The first sheet 230 includes the fluid inlets 104a-c. As described above, the fluid inlets 104a-c permit fluid to enter the plate assembly 120, and the actuators 122 can control the flow of fluid through the fluid inlets 104. The third sheet 250 includes a first cavity or depression 252a, a second cavity or depression 252b, and a third cavity or depression 252c (collectively referred to herein as the “cavities 252”). The upper surface of the cavities 252 can be slightly recessed relative to the upper surface of the third sheet 250 and are configured to align with the first actuator 122a and/or the first fluid inlet 104a, the second actuator 122b and/or the second fluid inlet 104b, and the third actuator 122c and/or the third fluid inlet 104c. Aligning the first actuator 122a, the second actuator 122b, and the third actuator 122c with the first cavity 252a, the second cavity 252b, and the third cavity 252c, respectively, prevents the upper surface of the third sheet 250 from interfering with (e.g., preventing movement of) the actuators 122. For example, a small gap can exist between at least a portion of the actuators 122 (e.g., the actuation elements and/or gating element) and the third sheet 250. In some embodiments, the cavities 252 only exist under the moveable portions of the actuators 122 (e.g., the actuation elements and gating elements). Furthermore, the first cavity 252a can collect fluid entering the plate assembly 120 via the first fluid inlet 104a, the second cavity 252b can collect fluid entering the plate assembly 120 via the second fluid inlet 104b, and the third cavity 252c can collect fluid entering the plate assembly 120 via the third fluid inlet 104c. The cavities 252 can be substantially fluidly isolated to provide greater control of the level of therapy provided by the system, as described in greater detail below.
The third sheet 250 also includes channels 254 for draining fluid through the plate assembly 120. In particular, the third sheet 250 includes a first channel 254a in fluid communication with the first cavity 252a, a second channel 254b in fluid communication with the second cavity 252b, and a third channel 254c in fluid communication with the third cavity 252c. Each of the channels 254 terminate in a fluid collection well 256 that can be fluidly coupled to or otherwise drain into the main fluid conduit(s) 110 of the elongated housing 102. Accordingly, in the embodiment shown in
As described above, fluid draining via the system 100 travels through the plate assembly 120 (and thus at least one of the channels 254). If the first actuator 122a is in the open position, fluid entering the plate assembly 120 via the first fluid inlet 104a (
The channels 254 can have different dimensions (e.g., length, width, height, cross-section area, etc.) such that each channel 254 provides a different resistance to flow. For example, the first channel 254a can provide a first resistance, the second channel 254b can provide a second resistance less than the first resistance, and the third channel 254c can provide a third resistance less than the second resistance. The therapy level (e.g., drainage rate of aqueous) provided by the system 100 can therefore be controlled by selectively controlling which route(s) through the plate assembly 120 are open to fluid flow. For example, to provide a first relatively small level of therapy, the first actuator 122a can be in an open position while the second actuator 122b and the third actuator 122c are in a closed position. Thus, the only route for fluid to drain through the system 100 is through the first channel 254a, which, as described above, has a relatively high resistance to flow. Thus, the drainage rate is relatively low. To provide a second relatively higher level of therapy, the third actuator 122c can be in an open position while the second actuator 122b and the first actuator 122a are in a closed position. Thus, the only route for fluid to drain through the system 100 is through the third channel 254c, which, as described above, has a relatively low resistance to flow. Thus, the drainage rate is relatively high. Of course, the actuators 122 can be selectively positioned at any combination of open and closed positions to provide the desired level of therapy. Additional details regarding providing multiple discrete therapy levels using shunting systems having a variety of fluid inlets and flow channels are described in International Patent Publication No. WO2021/151007, the disclosure of which is incorporated by reference herein in its entirety.
The plate assembly 320 still forms an enclosed cartridge, with the first sheet 230, the second sheet 240, the third sheet 250, and the fourth sheet 360 enclosing the actuation assembly 321, as best shown in
Furthermore, unlike the plate assemblies 120 and 320, the fourth sheet 460 of the plate assembly includes a first channel 454a, a second channel 454b, and a third channel 454c (collectively referred to herein as the “channels 454”), each of which can have different fluid resistances. Thus, in the embodiment shown in
The plate assembly 420 also includes a third sheet 450 that includes elongated depressions or wells 452 (e.g., a first depression 452a, a second depression 452b, and a third depression 452c). The depressions 452 can collect fluid entering via the inlets 104a-c to transport the fluid to the respective channels 454a-c to permit fluid to flow between the inlet 104 and the corresponding channel 454, e.g., when the corresponding actuation assembly 421 is in an open position. The depressions 452 accordingly form a channel-like path that fluid flows through the fluid flows through the plate assembly 420. The depressions 452 can therefore also be referred to as defining a “first portion” of the corresponding channels 454, rather than as separate features (e.g., the first depression 452a and the first channel 454a collectively form a first elongated flow channel, the second depression 452b and the second channel 454b collectively form a second elongated flow channel, etc.). In some embodiments, the third sheet 450 may be omitted from the plate assembly 420, and fluid can flow around the actuation assembly but within the empty space 462 to reach the channel 454.
As with the plate assemblies 120 and 320, the plate assembly 420 still forms an enclosed cartridge, with the first sheet 130, the second sheet 140, the third sheet 450, and the fourth sheet 460 enclosing the actuation assemblies 421, as best shown in
As one skilled in the art will appreciate, any of the plate assemblies described above can be used with the system 100 to control the flow of fluid therethrough. Moreover, certain features described with respect to one plate assembly can be added or combined with another plate assembly. Accordingly, the present technology is not limited to the plate assemblies expressly identified herein.
Incorporating a plate assembly such as those described above into adjustable shunting systems is expected to provide several advantages. For example, many of the components required to produce an adjustable shunting system capable of providing a titratable and adjustable therapy are very small and difficult to manufacture using conventional techniques for molding plastic, steel, or other non-transparent materials. In contrast, utilizing the plate assemblies described herein is expected to reduce the complexity of manufacturing. For example, the sheets of the plate assembly (e.g., the sheets 230-260 of the plate assembly 120) can be formed via known techniques for fabricating transparent materials that have a relatively high resolution (e.g., about 10 microns or less) and high reproducibility. In some embodiments, the sheets are formed using additive manufacturing processes with submicron resolution. Such techniques tend to have greater resolution than techniques for cutting nitinol, non-transparent plastics, steel, and other non-transparent materials, permitting greater control over the shape and flow characteristics of the plate assembly (e.g., providing eater control over the dimensions of the channels 254, etc.).
Another expected advantage is that in at least some embodiments, the plate assemblies or features thereof can be manufactured in bulk. For example, hundreds or even thousands of copies of a single component of the plate assembly (e.g., the first sheet can be etched or otherwise fabricated in a first disc or sheet of material. Copies of a second component (e.g., the second sheet of the plate assembly) can be etched or otherwise fabricated in a second disc or sheet of material, copies of a third component (e.g., the third sheet) can be etched or otherwise fabricated in a third disc or sheet of material, and so on. The discs or sheets of material can then be stacked such that individual first components align with individual second components, individual third components, and so on. The discs or other sheets of material can then be bonded or otherwise adhered, forming a plurality of plate assemblies. The formed plate assemblies can then simply be cut from the disc or other sheet of material in bulk, producing hundreds or even thousands of the plate assemblies. In some embodiments, these manufacturing techniques can be generally similar to fabrication techniques used to make integrated circuits and micro-electromechanical devices.
The present technology may provide additional advantages beyond those explicitly described above. For example, the present technology may provide enhanced surface quality for the plate assemblies and/or shunting systems, better mechanical properties of the plate assemblies and/or shunting systems, and/or enable a larger selection of materials to be used for fabricating the plate assemblies and/or shunting systems.
The present technology further includes methods of manufacturing the plate assemblies described herein. For example,
The method 500 can continue at step 504 by fabricating one or more actuation assemblies from a second material. This can include, for example, fabricating the one or more actuation assemblies from nitinol or another shape memory material via a photolithographic process, via a deposition process, via cutting or etching a unitary structure from a sheet or source material, or other suitable techniques for forming shape memory materials. In some embodiments, a single unitary actuation assembly is formed at step 504. In other embodiments, multiple discrete actuation assemblies are formed at step 504.
The method 500 can continue at step 506 by forming or assembling the sheets into a cartridge that encases the one or more actuation assemblies (e.g., thereby forming the plate assembly). This can be done by stacking the plates on top of one another and adhering adjacent plates to one another. In some embodiments, this includes gluing, welding, soldering, bonding or otherwise securing adjacent plates to one another. In some embodiments, this includes placing the sheets into a vacuum such that the sheets automatically self-bond to one another. The formed plate assembly can then optionally be positioned within an elongated housing to font a shunting system.
The method 600 can continue at step 604 by stacking the pieces of material on top of one another such that individual first components of the first piece of material align with individual second components of second piece of material, individual second components of the second piece of material align with individual third components of the third piece of material, individual third components of the third piece of material align with individual fourth components of the fourth piece of material, and individual fourth components of the fourth piece of material align with individual fifth components of the fifth piece of material. Of course, the pieces of material can be stacked in the order corresponding to the desired layered arrangement for the plate assembly.
The method 600 can continue at step 606 by bonding or otherwise adhering one or more of the stacked pieces of material to one another. This can include, for example, exposing the stacked pieces of material to a vacuum such that one or more of the stacked pieces automatically self-bond. In other embodiments, one or more of the stacked pieces of material can be glued or otherwise adhered together.
The method 600 can continue at step 608 by cutting individual plate assemblies from the stacked and adhered pieces of material. In some embodiments, hundreds or even thousands of plate assemblies can be cut from the stacked and adhered pieces of material.
Several aspects of the present technology are set forth in the following examples:
The above detailed description of embodiments of the technology are not intended to be exhaustive or to limit the technology to the precise form disclosed above. Although specific embodiments of, and examples for, the technology are described above for illustrative purposes, various equivalent modifications are possible within the scope of the technology as those skilled in the relevant art will recognize. For example, any of the features of the intraocular shunts described herein may be combined with any of the features of the other intraocular shunts described herein and vice versa. Moreover, although steps are presented in a given order, alternative embodiments may perform steps in a different order. The various embodiments described herein may also be combined to provide further embodiments.
From the foregoing, it will be appreciated that specific embodiments of the technology have been described herein for purposes of illustration, but well-known structures and functions associated with intraocular shunts have not been shown or described in detail to avoid unnecessarily obscuring the description of the embodiments of the technology. Where the context permits, singular or plural terms may also include the plural or singular term, respectively.
Unless the context clearly requires otherwise, throughout the description and the examples, the words “comprise,” “comprising,” and the like are to be construed in an inclusive sense, as opposed to an exclusive or exhaustive sense; that is to say, in the sense of “including but not limited to.” As used herein, the terms “connected,” “coupled,” or any variant thereof, means any connection or coupling, either direct or indirect, between two or more elements; the coupling of connection between the elements can be physical, logical, or a combination thereof. Additionally, the words “herein,” “above,” “below,” and words of similar import, when used in this application, shall refer to this application as a whole and not to any particular portions of this application. Where the context permits, words in the above Detailed Description using the singular or plural number may also include the plural or singular number respectively. As used herein, the phrase “and/or” as in “A and/or B” refers to A alone, B alone, and A and B. Additionally, the term “comprising” is used throughout to mean including at least the recited feature(s) such that any greater number of the same feature and/or additional types of other features are not precluded. It will also be appreciated that specific embodiments have been described herein for purposes of illustration, but that various modifications may be made without deviating from the technology. Further, while advantages associated with some embodiments of the technology have been described in the context of those embodiments, other embodiments may also exhibit such advantages, and not all embodiments need necessarily exhibit such advantages to fall within the scope of the technology. Accordingly, the disclosure and associated technology can encompass other embodiments not expressly shown or described herein.
This application is a 35 U.S.C. § 371 U.S. National Phase application of International Patent Application No. PCT/US2022/013336, filed Jan. 21, 2022, and titled ADJUSTABLE SHUNTING SYSTEMS WITH PLATE ASSEMBLIES, AND ASSOCIATED SYSTEMS AND METHODS, which claims priority to U.S. Provisional Patent Application No. 63/140,655, filed Jan. 22, 2021, each of which is herein incorporated by reference in its entirety.
Filing Document | Filing Date | Country | Kind |
---|---|---|---|
PCT/US2022/013336 | 1/21/2022 | WO |
Publishing Document | Publishing Date | Country | Kind |
---|---|---|---|
WO2022/159723 | 7/28/2022 | WO | A |
Number | Name | Date | Kind |
---|---|---|---|
4401107 | Harber et al. | Aug 1983 | A |
4595390 | Hakim et al. | Jun 1986 | A |
5070697 | Van Zeggeren | Dec 1991 | A |
5123906 | Kelman | Jun 1992 | A |
5476445 | Baerveldt et al. | Dec 1995 | A |
5601094 | Reiss | Feb 1997 | A |
6077298 | Tu et al. | Jun 2000 | A |
6077299 | Adelberg et al. | Jun 2000 | A |
6203513 | Yaron et al. | Mar 2001 | B1 |
6261256 | Ahmed | Jul 2001 | B1 |
6450984 | Lynch et al. | Sep 2002 | B1 |
6508779 | Suson | Jan 2003 | B1 |
6626858 | Lynch et al. | Sep 2003 | B2 |
6638239 | Bergheim et al. | Oct 2003 | B1 |
6666841 | Gharib et al. | Dec 2003 | B2 |
6736791 | Tu et al. | May 2004 | B1 |
6789447 | Zinck | Sep 2004 | B1 |
7025740 | Ahmed | Apr 2006 | B2 |
7207965 | Simon | Apr 2007 | B2 |
7354416 | Quiroz-Mereado et al. | Apr 2008 | B2 |
7458953 | Peyman | Dec 2008 | B2 |
7699882 | Stamper et al. | Apr 2010 | B2 |
7717872 | Shetty | May 2010 | B2 |
7947008 | Grahn et al. | May 2011 | B2 |
8012134 | Claude et al. | Sep 2011 | B2 |
8206333 | Schmidt et al. | Jun 2012 | B2 |
8206440 | Guarnieri | Jun 2012 | B2 |
8298240 | Giger et al. | Oct 2012 | B2 |
8308701 | Horvath et al. | Nov 2012 | B2 |
8414635 | Hyodoh et al. | Apr 2013 | B2 |
8506515 | Burns et al. | Aug 2013 | B2 |
8540659 | Berlin | Sep 2013 | B2 |
8579848 | Field et al. | Nov 2013 | B2 |
8585629 | Grabner et al. | Nov 2013 | B2 |
8663303 | Horvath et al. | Mar 2014 | B2 |
8702639 | Van Der Mooren et al. | Apr 2014 | B2 |
8721702 | Romoda et al. | May 2014 | B2 |
8753305 | Field et al. | Jun 2014 | B2 |
8758290 | Horvath et al. | Jun 2014 | B2 |
8765210 | Romoda et al. | Jul 2014 | B2 |
8771220 | Nissan et al. | Jul 2014 | B2 |
8801766 | Reitsamer et al. | Aug 2014 | B2 |
8828070 | Romoda et al. | Sep 2014 | B2 |
8852136 | Horvath et al. | Oct 2014 | B2 |
8852137 | Horvath et al. | Oct 2014 | B2 |
8852256 | Horvath et al. | Oct 2014 | B2 |
8882781 | Smedley et al. | Nov 2014 | B2 |
8915877 | Cunningham et al. | Dec 2014 | B2 |
8974511 | Horvath et al. | Mar 2015 | B2 |
9017276 | Horvath et al. | Apr 2015 | B2 |
9095411 | Horvath et al. | Aug 2015 | B2 |
9095413 | Romoda et al. | Aug 2015 | B2 |
9113994 | Horvath et al. | Aug 2015 | B2 |
9125723 | Horvath et al. | Sep 2015 | B2 |
9192516 | Horvath et al. | Nov 2015 | B2 |
9226851 | Gunn | Jan 2016 | B2 |
9271869 | Horvath et al. | Mar 2016 | B2 |
9283115 | Lind et al. | Mar 2016 | B2 |
9283116 | Romoda et al. | Mar 2016 | B2 |
9289324 | Johnson et al. | Mar 2016 | B2 |
9326891 | Horvath et al. | May 2016 | B2 |
9375347 | Stergiopulos | Jun 2016 | B2 |
9393153 | Horvath et al. | Jul 2016 | B2 |
9555410 | Brammer et al. | Jan 2017 | B2 |
9585789 | Silvestrini et al. | Mar 2017 | B2 |
9585790 | Horvath et al. | Mar 2017 | B2 |
9592154 | Romoda et al. | Mar 2017 | B2 |
9610195 | Horvath | Apr 2017 | B2 |
9636254 | Yu et al. | May 2017 | B2 |
9636255 | Haffner et al. | May 2017 | B2 |
9655778 | Tyler | May 2017 | B2 |
9655779 | Bigler et al. | May 2017 | B2 |
9693900 | Gallardo Inzunza | Jul 2017 | B2 |
9693901 | Horvath et al. | Jul 2017 | B2 |
9757276 | Penhasi | Sep 2017 | B2 |
9808373 | Horvath et al. | Nov 2017 | B2 |
9877866 | Horvath et al. | Jan 2018 | B2 |
9883969 | Horvath et al. | Feb 2018 | B2 |
9980854 | Horvath et al. | May 2018 | B2 |
10004638 | Romoda et al. | Jun 2018 | B2 |
10080682 | Horvath et al. | Sep 2018 | B2 |
10085884 | Reitsamer et al. | Oct 2018 | B2 |
10154924 | Clauson et al. | Dec 2018 | B2 |
10159600 | Horvath et al. | Dec 2018 | B2 |
10195078 | Horvath et al. | Feb 2019 | B2 |
10195079 | Horvath et al. | Feb 2019 | B2 |
10231871 | Hill | Mar 2019 | B2 |
10238536 | Olson et al. | Mar 2019 | B2 |
10285853 | Rangel-Friedman et al. | May 2019 | B2 |
10307293 | Horvath et al. | Jun 2019 | B2 |
10314743 | Romoda et al. | Jun 2019 | B2 |
10322267 | Hakim | Jun 2019 | B2 |
10369048 | Horvath et al. | Aug 2019 | B2 |
10405903 | Biesinger et al. | Sep 2019 | B1 |
10335030 | Alhourani | Oct 2019 | B2 |
10342703 | Siewert et al. | Nov 2019 | B2 |
10463537 | Horvath et al. | Nov 2019 | B2 |
10470927 | Horvath et al. | Nov 2019 | B2 |
10363168 | Schieber et al. | Dec 2019 | B2 |
10492948 | Baerveldt | Dec 2019 | B2 |
10524959 | Horvath | Jan 2020 | B2 |
10524958 | Camras et al. | Mar 2020 | B2 |
10596035 | Stergiopulos et al. | Apr 2020 | B2 |
10758412 | Velasquez | Apr 2020 | B2 |
10716663 | Salahich et al. | Jul 2020 | B2 |
11122975 | Rodger et al. | Jan 2021 | B2 |
10912675 | Lubatschowski | Feb 2021 | B2 |
11166847 | Badawi et al. | Feb 2021 | B2 |
10952897 | Smith | Mar 2021 | B1 |
10960074 | Berdahl | Mar 2021 | B2 |
11007061 | Passman et al. | May 2021 | B2 |
11039954 | Cohen et al. | Jun 2021 | B2 |
11058581 | Mixter et al. | Jul 2021 | B2 |
11065154 | Sponsel et al. | Jul 2021 | B1 |
11083624 | Stein et al. | Aug 2021 | B2 |
11166848 | Mixter et al. | Nov 2021 | B2 |
11166849 | Mixter et al. | Nov 2021 | B2 |
11291585 | Schultz et al. | Apr 2022 | B2 |
11517477 | Lilly et al. | Dec 2022 | B2 |
11529258 | Chang et al. | Dec 2022 | B2 |
11596550 | Chang et al. | Mar 2023 | B2 |
20010011585 | Cassidy et al. | Aug 2001 | A1 |
20020177891 | Miles et al. | Nov 2002 | A1 |
20020193725 | Odrich | Dec 2002 | A1 |
20030127090 | Gifford et al. | Jul 2003 | A1 |
20030163079 | Burnett | Aug 2003 | A1 |
20030183008 | Bang et al. | Oct 2003 | A1 |
20040010219 | McCusker et al. | Jan 2004 | A1 |
20040190153 | Esch | Sep 2004 | A1 |
20040193095 | Shadduck | Sep 2004 | A1 |
20040254520 | Porteous et al. | Dec 2004 | A1 |
20050049578 | Tu et al. | Mar 2005 | A1 |
20050059956 | Varner et al. | Mar 2005 | A1 |
20050196424 | Chappa | Sep 2005 | A1 |
20060004317 | Mauge et al. | Jan 2006 | A1 |
20060069340 | Simon | Mar 2006 | A1 |
20060155300 | Stamper et al. | Jul 2006 | A1 |
20060276739 | Brown | Dec 2006 | A1 |
20070010837 | Tanaka | Jan 2007 | A1 |
20070078371 | Brown et al. | Apr 2007 | A1 |
20070088432 | Solovay et al. | Apr 2007 | A1 |
20070265646 | McCoy et al. | Nov 2007 | A1 |
20070299487 | Shadduck | Dec 2007 | A1 |
20080077071 | Yaron et al. | Mar 2008 | A1 |
20080119891 | Miles et al. | May 2008 | A1 |
20080125691 | Yaron et al. | May 2008 | A1 |
20080277332 | Liu | Nov 2008 | A1 |
20090012483 | Blott et al. | Jan 2009 | A1 |
20090036818 | Grahn et al. | Feb 2009 | A1 |
20090043321 | Conston et al. | Feb 2009 | A1 |
20090243956 | Keilman et al. | Oct 2009 | A1 |
20090287136 | Castillejos | Nov 2009 | A1 |
20090314970 | MCAvoy et al. | Dec 2009 | A1 |
20090326517 | Bork et al. | Dec 2009 | A1 |
20100114006 | Baerveldt | May 2010 | A1 |
20100234791 | Lynch et al. | Sep 2010 | A1 |
20100241077 | Geipel et al. | Sep 2010 | A1 |
20100249691 | Van Der Mooren et al. | Sep 2010 | A1 |
20110105986 | Bronstein et al. | May 2011 | A1 |
20120035525 | Silvestrini | Feb 2012 | A1 |
20120065570 | Yeung et al. | Mar 2012 | A1 |
20120089073 | Cunningham, Jr. | Apr 2012 | A1 |
20120232461 | Seaver et al. | Sep 2012 | A1 |
20130085440 | Bohm et al. | Apr 2013 | A1 |
20130131577 | Bronstein et al. | May 2013 | A1 |
20130150773 | Nissan et al. | Jun 2013 | A1 |
20130150776 | Bohm et al. | Jun 2013 | A1 |
20130158381 | Rickard | Jun 2013 | A1 |
20130197621 | Ryan et al. | Aug 2013 | A1 |
20130199646 | Brammer et al. | Aug 2013 | A1 |
20130205923 | Brammer et al. | Aug 2013 | A1 |
20130211312 | Gelvin | Aug 2013 | A1 |
20130267887 | Kahook et al. | Oct 2013 | A1 |
20130317412 | Dacquay et al. | Nov 2013 | A1 |
20130338564 | Rickard et al. | Dec 2013 | A1 |
20140046439 | Dos Santos et al. | Feb 2014 | A1 |
20140081195 | Clauson et al. | Mar 2014 | A1 |
20140309611 | Wilt et al. | Oct 2014 | A1 |
20150011926 | Reitsamer et al. | Jan 2015 | A1 |
20150034217 | Vad | Feb 2015 | A1 |
20150045716 | Gallardo Inzunza | Feb 2015 | A1 |
20150142049 | Delgado et al. | May 2015 | A1 |
20150230843 | Palmer et al. | Aug 2015 | A1 |
20150265469 | Olson et al. | Sep 2015 | A1 |
20150313603 | Bodewadt et al. | Nov 2015 | A1 |
20160151179 | Favier et al. | Jun 2016 | A1 |
20160220794 | Negre | Aug 2016 | A1 |
20160256317 | Horvath et al. | Sep 2016 | A1 |
20160256318 | Horvath et al. | Sep 2016 | A1 |
20160256319 | Horvath et al. | Sep 2016 | A1 |
20160256320 | Horvath et al. | Sep 2016 | A1 |
20160287439 | Stergiopulos | Oct 2016 | A1 |
20160354244 | Horvath et al. | Dec 2016 | A1 |
20160354245 | Horvath et al. | Dec 2016 | A1 |
20170027582 | Khoury et al. | Feb 2017 | A1 |
20170071791 | Piven | Mar 2017 | A1 |
20170087016 | Camras | Mar 2017 | A1 |
20170172797 | Horvath et al. | Jun 2017 | A1 |
20170172798 | Horvath et al. | Jun 2017 | A1 |
20170172799 | Horvath | Jun 2017 | A1 |
20170312125 | Clauson et al. | Nov 2017 | A1 |
20170348149 | Stergiopulos et al. | Dec 2017 | A1 |
20170348150 | Horvath et al. | Dec 2017 | A1 |
20180014828 | Fonte et al. | Jan 2018 | A1 |
20180028361 | Haffner et al. | Feb 2018 | A1 |
20180028366 | Tout et al. | Feb 2018 | A1 |
20180092775 | de Juan, Jr. et al. | Apr 2018 | A1 |
20180147089 | Horvath et al. | May 2018 | A1 |
20180177633 | Haffner et al. | Jun 2018 | A1 |
20180206878 | Uspenski et al. | Jul 2018 | A1 |
20180250166 | Lubatschowski | Sep 2018 | A1 |
20180333296 | Heitzmann et al. | Nov 2018 | A1 |
20190000673 | Fjield et al. | Jan 2019 | A1 |
20190021907 | Horvath et al. | Jan 2019 | A1 |
20190038462 | Vandiest et al. | Feb 2019 | A1 |
20190046356 | Laroche | Feb 2019 | A1 |
20190060118 | Hill | Feb 2019 | A1 |
20190133826 | Horvath et al. | Mar 2019 | A1 |
20190121278 | Kawamura et al. | Apr 2019 | A1 |
20190142632 | Badawi et al. | May 2019 | A1 |
20190151079 | Zaldivar | May 2019 | A1 |
20190167475 | Horvath et al. | Jun 2019 | A1 |
20190240069 | Horvath et al. | Aug 2019 | A1 |
20190247231 | McClunan | Aug 2019 | A1 |
20190254873 | Carras et al. | Aug 2019 | A1 |
20190274881 | Romoda et al. | Sep 2019 | A1 |
20190274882 | Romoda et al. | Sep 2019 | A1 |
20190307608 | Lee et al. | Oct 2019 | A1 |
20190344057 | Cima et al. | Nov 2019 | A1 |
20190350758 | Horvath et al. | Nov 2019 | A1 |
20190353269 | Ossmer et al. | Nov 2019 | A1 |
20190358086 | Camras et al. | Nov 2019 | A1 |
20190374384 | Xie et al. | Dec 2019 | A1 |
20200069469 | Horvath et al. | Mar 2020 | A1 |
20200085620 | Euteneuer et al. | Mar 2020 | A1 |
20200121503 | Badawi et al. | Apr 2020 | A1 |
20200121504 | Stegmann et al. | Apr 2020 | A1 |
20200129332 | Van Der Mooren et al. | Apr 2020 | A1 |
20200170839 | Borrmann et al. | Jun 2020 | A1 |
20200179171 | Crimaldi et al. | Jun 2020 | A1 |
20200214891 | Bigler et al. | Jul 2020 | A1 |
20200229977 | Mixter et al. | Jul 2020 | A1 |
20200229980 | Horvath | Jul 2020 | A1 |
20200229981 | Mixter et al. | Jul 2020 | A1 |
20200229982 | Mixter et al. | Jul 2020 | A1 |
20200246188 | Horvath et al. | Aug 2020 | A1 |
20200253725 | Hadba et al. | Aug 2020 | A1 |
20200261271 | Horvath et al. | Aug 2020 | A1 |
20200276050 | Simons et al. | Sep 2020 | A1 |
20200306086 | Da Silva Curiel et al. | Oct 2020 | A1 |
20200345549 | Lu et al. | Nov 2020 | A1 |
20210015665 | Hacker et al. | Jan 2021 | A1 |
20210030590 | Blanda et al. | Feb 2021 | A1 |
20210038158 | Haffner et al. | Feb 2021 | A1 |
20210069486 | Hakim | Mar 2021 | A1 |
20210106462 | Sherwood et al. | Apr 2021 | A1 |
20210128357 | de Juan, Jr. et al. | May 2021 | A1 |
20210137736 | Cavuto et al. | May 2021 | A1 |
20210161713 | Bouremel et al. | Jun 2021 | A1 |
20210196516 | Lanchulev | Jul 2021 | A1 |
20210205132 | Horvath et al. | Jul 2021 | A1 |
20210212858 | Tran et al. | Jul 2021 | A1 |
20210251806 | Schultz et al. | Aug 2021 | A1 |
20210282922 | Cohen-Tzemaeh et al. | Sep 2021 | A1 |
20210298948 | Haffner et al. | Sep 2021 | A1 |
20210315806 | Haffner | Oct 2021 | A1 |
20210330499 | Wardle et al. | Oct 2021 | A1 |
20220087865 | Argento et al. | Mar 2022 | A1 |
20220142818 | Chang et al. | May 2022 | A1 |
20220160545 | Mixter et al. | May 2022 | A1 |
20220160546 | Mixter et al. | May 2022 | A1 |
20220168146 | Badawi et al. | Jun 2022 | A1 |
20220202613 | Chang et al. | Jun 2022 | A1 |
20220241565 | Nae et al. | Aug 2022 | A1 |
20220273491 | Brown | Sep 2022 | A1 |
20220339035 | Lilly et al. | Oct 2022 | A1 |
20220354695 | Badawi et al. | Nov 2022 | A1 |
20220387216 | Schultz et al. | Dec 2022 | A1 |
20220387217 | Argento et al. | Dec 2022 | A1 |
20230086856 | Chang et al. | Mar 2023 | A1 |
20230092196 | Argento et al. | Mar 2023 | A1 |
Number | Date | Country |
---|---|---|
2014200171 | Jan 2014 | AU |
2014201621 | Mar 2016 | AU |
2016201445 | Mar 2016 | AU |
2018200325 | Feb 2018 | AU |
2017274654 | Dec 2018 | AU |
2020201818 | Apr 2020 | AU |
2017439185 | May 2020 | AU |
2018412569 | Oct 2020 | AU |
112017025859 | Aug 2018 | BR |
112020008969 | Oct 2020 | BR |
2987953 | Dec 2016 | CA |
3080713 | May 2019 | CA |
3093160 | Sep 2019 | CA |
104490515 | Apr 2015 | CN |
106726124 | May 2017 | CN |
108743016 | Nov 2018 | CN |
111405875 | Jul 2020 | CN |
2020011460 | Nov 2020 | CO |
10217061 | Mar 2003 | DE |
102010015447 | Oct 2011 | DE |
102017124885 | Apr 2019 | DE |
102018112065 | Nov 2019 | DE |
102019204846 | Oct 2020 | DE |
1292256 | Mar 2003 | EP |
1737531 | Jan 2007 | EP |
2552369 | Jan 2017 | EP |
3302381 | Apr 2018 | EP |
1765234 | Oct 2019 | EP |
2999430 | Nov 2019 | EP |
2677981 | Apr 2020 | EP |
3659495 | Jun 2020 | EP |
3518846 | Aug 2020 | EP |
3666236 | Aug 2020 | EP |
3687374 | Aug 2020 | EP |
3706653 | Sep 2020 | EP |
3730104 | Oct 2020 | EP |
3735947 | Nov 2020 | EP |
3773377 | Feb 2021 | EP |
3846747 | Jul 2021 | EP |
3846748 | Jul 2021 | EP |
3329884 | Aug 2021 | EP |
2389138 | Sep 2021 | EP |
3870120 | Sep 2021 | EP |
3313335 | Nov 2021 | EP |
2725550 | Sep 2019 | ES |
1252748 | May 2019 | HK |
E043303 | Aug 2019 | HU |
5576427 | Aug 2014 | JP |
2018519892 | Jul 2018 | JP |
2018130580 | Aug 2018 | JP |
2019517366 | Jun 2019 | JP |
2019205934 | Dec 2019 | JP |
2020049361 | Apr 2020 | JP |
2018015684 | Feb 2018 | KR |
20190019966 | Feb 2019 | KR |
20200021551 | Feb 2020 | KR |
20200059305 | May 2020 | KR |
2640455 | Aug 2019 | PL |
2640455 | May 2019 | PT |
2687764 | May 2019 | RU |
2018142990 | Jun 2020 | RU |
11202008604 | Oct 2020 | SG |
201906873 | Jun 2019 | TR |
WO2004081613 | Sep 2004 | WO |
WO2007011302 | Jan 2007 | WO |
WO2010111528 | Sep 2010 | WO |
WO2014130574 | Aug 2014 | WO |
WO2016100500 | Jun 2016 | WO |
WO2016149425 | Sep 2016 | WO |
WO2016196841 | Dec 2016 | WO |
WO2018229766 | Dec 2018 | WO |
WO2019094004 | May 2019 | WO |
WO2019165053 | Aug 2019 | WO |
WO2019172940 | Sep 2019 | WO |
WO2020150663 | Jul 2020 | WO |
WO2020215068 | Oct 2020 | WO |
WO2020223491 | Nov 2020 | WO |
WO2020231993 | Nov 2020 | WO |
WO2020247365 | Dec 2020 | WO |
WO2020261184 | Dec 2020 | WO |
WO2021007294 | Jan 2021 | WO |
WO2021007296 | Jan 2021 | WO |
WO2021028703 | Feb 2021 | WO |
WO2021068078 | Apr 2021 | WO |
WO2021072315 | Apr 2021 | WO |
WO2021072317 | Apr 2021 | WO |
WO2021113730 | Jun 2021 | WO |
WO2021142255 | Jul 2021 | WO |
WO2021151007 | Jul 2021 | WO |
WO2021163566 | Aug 2021 | WO |
WO2021168130 | Aug 2021 | WO |
WO2021174298 | Sep 2021 | WO |
WO2021176332 | Sep 2021 | WO |
WO2021188952 | Sep 2021 | WO |
WO2021204312 | Oct 2021 | WO |
WO2021212007 | Oct 2021 | WO |
WO2021230887 | Nov 2021 | WO |
WO2022175681 | Aug 2022 | WO |
WO2022220861 | Oct 2022 | WO |
WO2023004067 | Jan 2023 | WO |
WO2023278452 | Jan 2023 | WO |
WO2023009366 | Feb 2023 | WO |
WO2023063961 | Apr 2023 | WO |
WO2023064491 | Apr 2023 | WO |
WO2023091307 | May 2023 | WO |
WO2023107486 | Jun 2023 | WO |
201708295 | May 2020 | ZA |
Entry |
---|
International Search Report and Written Opinion received for PCT Application No. PCT/US22/35324, filed on Jun. 28, 2022, Applicant: Shifamed Holdings, LLC, dated Nov. 22, 2022, 12 pages. |
International Search Report and Written Opinion received for PCT Application No. PCT/US22/37917, filed on Jul. 21, 2022, Applicant: Shifamed Holdings, LLC, dated Dec. 15, 2022, 15 pages. |
Keulegan et al. “Pressure Losses for Fluid Flow in Curved Pipes,” Journal of Research of the National Bureau of Standards, vol. 18, Jan. 31, 1937 (Jan. 31, 1937), 26 pages. |
Olsen et al. “Human sclera: thickness and surface area,” American Journal of Ophthalmology, vol. 125, Issue. 2, https://pubmed.ncbi.nlm.nih.gov/9467451, Feb. 1, 1998 (Feb. 1, 1998), 1 page. |
International Search Report and Written Opinion received for PCT Application No. PCT/US22/048863, filed on Nov. 3, 2022, Applicant: Shifamed Holdings, LLC, dated Feb. 16, 2023, 13 pages. |
International Search Report and Written Opinion received for PCT Application No. PCT/US18/43158, filed on Jul. 20, 2018, Applicant: Shifamed Holdings, LLC, dated Nov. 23, 2018, 12 pages. |
International Search Report and Written Opinion received for PCT Application No. PCT/US20/14186, filed on Jan. 17, 2020, Applicant: Shifamed Holdings, LLC, dated Jun. 4, 2020, 13 pages. |
International Search Report and Written Opinion received for PCT Application No. PCT/US21/14774, filed on Jan. 22, 2021, Applicant: Shifamed Holdings, LLC, dated May 12, 2021, 10 pages. |
International Search Report and Written Opinion received for PCT Application No. PCT/US21/17962, filed on Feb. 12, 2021, Applicant: Shifamed Holdings, LLC, dated Jun. 7, 2021, 12 pages. |
International Search Report and Written Opinion received for PCT Application No. PCT/US21/23238, filed on Mar. 19, 2021, Applicant: Shifamed Holdings, LLC, dated Jul. 8, 2021, 10 pages. |
International Search Report and Written Opinion received for PCT Application No. PCT/US21/18601, filed on Feb. 18, 2021, Applicant: Shifamed Holdings, LLC, dated Jul. 19, 2021, 12 pages. |
International Search Report and Written Opinion received for PCT Application No. PCT/US21/27742, filed on Apr. 16, 2021, Applicant: Shifamed Holdings, LLC, dated Oct. 7, 2021, 13 pages. |
International Search Report and Written Opinion received for PCT Application No. PCT/US21/49140, filed on Sep. 3, 2021, Applicant: Shifamed Holdings, LLC, dated Dec. 7, 2021, 22 pages. |
International Search Report and Written Opinion received for PCT Application No. PCT/US21/55258, filed on Oct. 15, 2021, Applicant: Shifamed Holdings, LLC, dated Feb. 28, 2022, 18 pages. |
International Search Report and Written Opinion received for PCT Application No. PCT/US20/55144, filed on Oct. 9, 2020, Applicant: Shifamed Holdings, LLC, dated Feb. 1, 2021, 16 pages. |
International Search Report and Written Opinion received for PCT Application No. PCT/US20/55141, filed on Oct. 9, 2020, Applicant: Shifamed Holdings, LLC, dated Jan. 29, 2021, 11 pages. |
International Search Report and Written Opinion received for PCT Application No. PCT/US22/13336, filed on Jan. 21, 2022, Applicant: Shifamed Holdings, LLC, dated Apr. 11, 2022, 9 pages. |
International Search Report and Written Opinion received for PCT Application No. PCT/US22/52002, filed on Dec. 6, 2022, Applicant: Shifamed Holdings, LLC, dated Mar. 21, 2023, 11 pages. |
International Search Report and Written Opinion received for PCT Application No. PCT/US22/46604, filed on Oct. 13, 2022, Applicant: Shifamed Holdings, LLC, dated Mar. 30, 2023, 11 pages. |
Number | Date | Country | |
---|---|---|---|
20230201544 A1 | Jun 2023 | US |
Number | Date | Country | |
---|---|---|---|
63140655 | Jan 2021 | US |